When using the same cutoff to analyze the data from the current study, overall prevalence of MAGE-A4 positivity was similar (15.5%), while indications with ≥20% prevalence of MAGE-A4 positivity were squamous cell NSCLC (55%), gastric cancer (43%), esophageal cancer (38%), adenoid cystic carcinoma (36%), liposarcoma (33%), synovial sarcoma (33%), ovarian cancer (21% for serous/high grade, 22% for other), and endometrial cancer (20%; refer to Supplementary Table 4 for information on all samples analyzed in this study). This evidence concerns the gene MAGEA4 and ovarian carcinoma.